Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck’s end-stage renal disease therapy secures FDA fast track designation
The MK-2060 has been approved to reduce the risk of major thrombotic cardiovascular events in end-stage renal disease patients. Credit: Robina Weermeijer on Unsplash.
The MK-2060 has been approved to reduce the risk of major thrombotic cardiovascular events in end-stage renal disease patients. Credit: Robina Weermeijer on Unsplash.